| 1. |
|
|
| 2. |
|
|
| 3. |
- Brunnström, Hans, et al.
(author)
-
Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the southern Swedish lung cancer study.
- 2013
-
In: American Journal of Clinical Pathology. - 1943-7722. ; 140:1, s. 37-46
-
Journal article (peer-reviewed)abstract
- Objectives: To assess immunohistochemical (IHC) stains differentially expressed between different types of lung cancer. Methods: We evaluated 16 different IHC stains in 209 prospectively included, surgically treated primary lung cancers, including 121 adenocarcinomas, 65 squamous cell carcinomas, 15 large-cell carcinomas, 5 adenosquamous carcinomas, 2 sarcomatoid carcinomas, and 1 small-cell carcinoma, using the tissue microarray technique. Results: Cytokeratin 5 (CK5) and P63 were both positive in 10% or more of the cells in 97% of the squamous cell carcinomas, with the former being positive (<10% of the cells) in only 2 non-squamous cell carcinomas. Thyroid transcription factor 1 (TTF1) and napsin A were positive in 10% or more of the cells in 88% and 87% of the adenocarcinomas, respectively, with 94% of the adenocarcinomas being positive in at least 1 marker. Fifteen percent of the adenocarcinomas were positive for estrogen receptor. Conclusions: CK5, TTF1, and napsin A are sensitive markers for squamous cell carcinoma and adenocarcinoma of the lung.
|
|
| 4. |
- Dragomir, Anca, et al.
(author)
-
The Role of SATB2 as a Diagnostic Marker for Tumors of Colorectal Origin
- 2014
-
In: American Journal of Clinical Pathology. - 0002-9173 .- 1943-7722. ; 141:5, s. 630-638
-
Journal article (peer-reviewed)abstract
- Objectives: Immunohistochemistry is an important extension to clinical information and morphology, and prevails as an invaluable tool for establishing a correct cancer diagnosis in clinical diagnostic pathology. The applicability of immunohistochemistry is limited by the availability of validated cell- and cancer-type specific antibodies, rendering an unmet need to discover, test, and validate novel markers. The SATB2 protein is selectively expressed in glandular cells from the lower gastrointestinal tract and expression is retained in a large majority of primary and metastatic colorectal cancers. Methods: We analyzed the expression of SATB2 in all clinical cases (n = 840), in which immunohistochemistry for detection of CK20 was deemed necessary for a final diagnosis. Results: SATB2 showed a high sensitivity (93%) and specificity (77%) to determine a cancer of colorectal origin and in combination with CK7 and CK20, the specificity increased to 100%. Conclusions: We conclude that SATB2 provides a new and advantageous supplement for clinical differential diagnostics.
|
|
| 5. |
- Dragomir, Anca, et al.
(author)
-
The role of SATB2 as a diagnostic marker for tumors of colorectal origin : Results of a pathology-based clinical prospective study
- 2014
-
In: American Journal of Clinical Pathology. - 0002-9173 .- 1943-7722. ; 141:5, s. 630-638
-
Journal article (peer-reviewed)abstract
- OBJECTIVES: Immunohistochemistry is an important extension to clinical information and morphology, and prevails as an invaluable tool for establishing a correct cancer diagnosis in clinical diagnostic pathology. The applicability of immunohistochemistry is limited by the availability of validated cell- and cancer-type specific antibodies, rendering an unmet need to discover, test, and validate novel markers. The SATB2 protein is selectively expressed in glandular cells from the lower gastrointestinal tract and expression is retained in a large majority of primary and metastatic colorectal cancers.METHODS: We analyzed the expression of SATB2 in all clinical cases (n = 840), in which immunohistochemistry for detection of CK20 was deemed necessary for a final diagnosis.RESULTS: SATB2 showed a high sensitivity (93%) and specificity (77%) to determine a cancer of colorectal origin and in combination with CK7 and CK20, the specificity increased to 100%.CONCLUSIONS: We conclude that SATB2 provides a new and advantageous supplement for clinical differential diagnostics.
|
|
| 6. |
|
|
| 7. |
|
|
